In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor

Zhou, 2005, The role of the tumor microenvironment in hematological malignancies and implication for therapy, Front Biosci, 10, 1581, 10.2741/1642 Gerber, 2002, VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism, Nature, 417, 954, 10.1038/nature00821 Millauer, 1993, High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis, Cell, 72, 835, 10.1016/0092-8674(93)90573-9 Terman, 1992, Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor, Biochem Biophys Res Commun, 187, 1579, 10.1016/0006-291X(92)90483-2 Waltenberger, 1994, Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor, J Biol Chem, 269, 26988, 10.1016/S0021-9258(18)47116-5 Koomagi, 2001, Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction, Clin Cancer Res, 7, 3381 Fiedler, 1997, Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia, Blood, 89, 1870, 10.1182/blood.V89.6.1870 Hussong, 2000, Evidence of increased angiogenesis in patients with acute myeloid leukemia, Blood, 95, 309, 10.1182/blood.V95.1.309 Bellamy, 2001, Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes, Blood, 97, 1427, 10.1182/blood.V97.5.1427 Aguayo, 2001, Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL), Leuk Res, 25, 279, 10.1016/S0145-2126(00)00139-9 Verstovsek, 2003, Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia, Leuk Res, 27, 661, 10.1016/S0145-2126(02)00275-8 Bellamy, 1999, Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies, Cancer Res, 59, 728 Nagy, 2002, Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis, J Exp Med, 196, 1497, 10.1084/jem.20021244 Podar, 2005, The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications, Blood, 105, 1383, 10.1182/blood-2004-07-2909 Dias, 2000, Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration, J Clin Investig, 106, 511, 10.1172/JCI8978 List, 2004, Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells, Exp Hematol, 32, 526, 10.1016/j.exphem.2004.03.005 Santos, 2004, Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways, Blood, 103, 3883, 10.1182/blood-2003-05-1634 Schuch, 2002, In vivo administration of vascular endothelial growth factor (VEGF) and its antagonist, soluble neuropilin-1, predicts a role of VEGF in the progression of acute myeloid leukemia in vivo, Blood, 100, 4622, 10.1182/blood.V100.13.4622 Fragoso, 2006, VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease, Blood, 107, 1608, 10.1182/blood-2005-06-2530 Hattori, 2002, Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment, Nat Med, 8, 841, 10.1038/nm740 Kaplan, 2005, VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche, Nature, 438, 820, 10.1038/nature04186 Fiedler, 2005, A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease, Blood, 105, 986, 10.1182/blood-2004-05-1846 O’Farrell, 2003, An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients, Clin Cancer Res, 9, 5465 Roboz, 2006, Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome, Leukemia, 20, 952, 10.1038/sj.leu.2404213 Albert, 2006, Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor, Mol Cancer Ther, 5, 995, 10.1158/1535-7163.MCT-05-0410 Guo, 2006, Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors, Mol Cancer Ther, 5, 1007, 10.1158/1535-7163.MCT-05-0359 Shankar, 2007, ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia, Blood, 109, 3400, 10.1182/blood-2006-06-029579 Zhou, 2007, Synergistic antileukemic effects between ABT-869 and chemotherapy involve downregulation of cell cycle-regulated genes and c-Mos-mediated MAPK pathway, Leukemia Yamauchi, 2006, Development of real-time subcellular dynamic multicolor imaging of cancer-cell trafficking in live mice with a variable-magnification whole-mouse imaging system, Cancer Res, 66, 4208, 10.1158/0008-5472.CAN-05-3927 Poon, 2002, Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study, J Clin Oncol, 20, 1775, 10.1200/JCO.2002.07.089 Shen, 2007, Synergistic antileukemia effect of genistein and chemotherapy in mouse xenograft model and potential mechanism through MAPK signaling, Exp Hematol, 35, 75, 10.1016/j.exphem.2006.09.007 Bergers, 2003, Tumorigenesis and the angiogenic switch, Nat Rev Cancer, 3, 401, 10.1038/nrc1093 Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669 Folkman, 2007, Angiogenesis: an organizing principle for drug discovery?, Nat Rev Drug Discov, 6, 273, 10.1038/nrd2115 Gerber, 2003, The role of VEGF in normal and neoplastic hematopoiesis, J Mol Med, 81, 20, 10.1007/s00109-002-0397-4 Fusetti, 2000, Cancer Res, 60, 2527 Dias, 2002, Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy, Blood, 99, 2179, 10.1182/blood.V99.6.2179 Katoh, 1998, Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor, Cancer Res, 58, 5565 Kulimova, 2006, Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors, Mol Cancer Ther, 5, 3105, 10.1158/1535-7163.MCT-06-0323 Hoffman, 2005, The multiple uses of fluorescent proteins to visualize cancer in vivo, Nat Rev Cancer, 5, 796, 10.1038/nrc1717 Yang, 2002, Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model, Proc Natl Acad Sci USA, 99, 3824, 10.1073/pnas.052029099